Echosens Announces NICE, UK Health Technology Assessment Organization, Issues MedTech Innovation Briefing on FibroScan Liver Exam in Primary Care
6.7.2020 16:00:00 EEST | Business Wire | Press release
Echosens, a high-technology company offering the FibroScan family of products, announces today that the National Institute for Health and Care Excellence (NICE), the United Kingdom’s health technology assessment body providing national guidance and advice to improve health and social care, issued a MedTech Innovation Briefing (MIB) dedicated to utilization of FibroScan non-invasive technology in the primary care setting. The NICE experts concurred that this approach could provide a cost-effective way for the National Health System (NHS) to assess liver fibrosis and cirrhosis in primary care--reducing the need for treatment, referrals and biopsies, and improving accuracy and speed.
“Using FibroScan as an interventional therapy helps primary care physicians and nurse specialists engage patients by demonstrating the results and outcomes as a value change that patients can visualize on a regular basis and give them confidence that their efforts have an impact,” says Louise Campbell, patient advocate, nurse consultant, founder and medical director of Tawazun Health, and NICE expert commentator. "The real value is that, in terms of battling the liver disease epidemic, it’s better to locate it early and be able to guide patient lifestyle changes than rely on costly drug therapies. Weight loss and exercise are the first step in mitigating liver damage.”
Non-alcoholic fatty liver disease (NAFLD) is a spectrum of the disease characterized by the accumulation of lipids in liver cells not associated with the consumption of alcohol. Its more severe form, non-alcoholic steatohepatitis (NASH) is an asymptomatic, progressive and burgeoning liver disease that can lead to increased liver-related mortality and morbidity. Both are major risk factors for concurrent conditions, including obesity, Type 2 diabetes and hyperlipidemia, and should be monitored to prevent fibrosis, cirrhosis, liver cancer and liver transplant.
The panel of NICE experts agreed that other technologies fail to offer the same benefits as FibroScan, which is highly portable, less expensive and requires minimal training time. NICE guidance supports the U.K. National Health Service for social care commissioners and staff who are considering using new medical devices and other medical or diagnostic technologies.
According to NICE advice, traditional approaches to assessing liver health non-invasively, such as MRI, CT, ultrasound acoustic radiation force impulse, shear wave elastography and blood biomarkers, as well as invasive liver biopsy, may not be accessible to the broader at-risk population or yield direct measurements. FibroScan based scores such as FAST, combine direct measurements of liver stiffness and fat, as well as circulating biomarkers of inflammation, for a more cost-effective assessment of active fibrotic NASH in patients suspected of having NAFLD.
This technology can be used by anyone who has completed training, leading to patients requiring fewer hospital visits and reducing wait times at secondary care centers (urgent care). According to MIB experts, 9 in 10 people sent to specialist care could have been managed in primary care, where patients can be identified for endoscopy or begin alcohol detox management to reduce emergency department visits. This is more likely to occur at a large practice by a healthcare professional on behalf of the primary care physician.
Dominique Legros, Echosens Group CEO, based at the corporate headquarters and offices in Paris, France, says, “Many patients are asymptomatic but, given the high prevalence of liver disease, FibroScan enables primary care physicians to provide a non-invasive way to examine liver health at the point of care with a dedicated non-invasive technology.”
About Echosens
Pioneer in its field, Echosens significantly changed the practice of liver diagnosis with FibroScan®, the non-invasive gold standard solution for comprehensive management of liver health. FibroScan® is recognized worldwide as the reference for non-invasive liver fibrosis and liver steatosis assessment with more than 2,500+ peer reviewed publications and 60+ international guidelines recommendations. Echosens has made FibroScan® available in over 100+ countries enabling millions of liver examinations worldwide.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200706005301/en/
Contact information
Brittany Tedesco
CPR Communications
btedesco@cpronline.com
201.641.1911 x 14
Claire Mario
claire.mario@echosens.com
+33(0)1-44-82-78-50
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KŌZĒ Stays Launches International Expansion with More Than 1,200 Properties18.11.2026 15:28:00 EET | Press release
KŌZĒ Stays announces a major international expansion, bringing its curated portfolio to more than 1,200 properties worldwide. Following eight consecutive years of rapid growth, the company is building on its established presence in Mont-Tremblant and the Laurentians to pursue a broader ambition in international hospitality. The expanded collection spans French and Swiss alpine chalets, Riviera villas near Monaco, Lake Como residences, private retreats in St. Barths and homes on Dubai’s Palm Jumeirah. Available through The KŌZĒ Collection, these properties extend the brand’s reach into some of the world’s most sought-after destinations. Canadian Roots, International Ambition “A guest who loves their stay with us in Mont-Tremblant should be able to book their next trip, whether that’s Verbier, St. Barths or Lake Como, knowing the KŌZĒ standard travels with them,” said Jeffery Khoury, Founder and CEO of KŌZĒ Stays. “That’s what this expansion is about: one name you trust, wherever you tra
Blue Yonder Announces New Leadership18.11.2026 15:03:00 EET | Press release
Blue Yonder, the AI company for supply chain, today announced that Salil Joshi has been named interim Chief Executive Officer. Joshi has most recently served as Blue Yonder’s Chief Technology Officer, where he led the company’s technology vision and growth strategy across the digital supply chain. Joshi succeeds Duncan Angove, who will transition out of the CEO role after four years leading the company. The Blue Yonder Board appreciates the contributions that Angove has made to the company. “Blue Yonder continues to showcase strong momentum through accelerating Cognitive Solutions adoption in the market. Blue Yonder has reported impressive SaaS ARR growth, adding new customer logos and increasing inclusions in key tech and industry analyst reports,” said Ken Sain, Chairman of the Blue Yonder Board of Directors and CEO of Panasonic Connect Group. “We believe there is a significant additional opportunity to build on that solid foundation to expand the company’s software platform to help
AI Private Markets Platform FinBursa Appoints Angelica Tigan as Chief Revenue Officer to Drive US and Global Growth18.11.2026 15:00:00 EET | Press release
FinBursa, the intelligent front office for private markets, has appointed Angelica Tigan, a former BlackRock and eFront sales leader, as Chief Revenue Officer to lead its global commercial expansion following the launch of FinBursa 360. Based in the US, Tigan will lead sales and partnerships worldwide, with an immediate focus on the US. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118596329/en/ Angelica Tigan, based in New York City, joins FinBursa as Chief Revenue Officer Tigan brings close to two decades in private markets technology, having built, led and scaled sales teams at BlackRock (Aladdin) and eFront, with previous experience at Intralinks and Gen II Fund Services. FinBursa 360 is an all-in-one platform for private equity, private credit, real estate, venture capital and M&A advisory firms, family offices, wealth managers, placement agents and fund administrators. It brings investment CRM, deal flow and deal m
Scientist.com Launches Pharma Observatory, an Agent-First Market Intelligence Platform for Biopharma R&D18.11.2026 14:55:00 EET | Press release
Scientist.com, the leading AI-enabled R&D orchestration platform and marketplace for the life science industry, today announced the launch of Pharma Observatory, a market intelligence platform that shows biopharma teams where their programs sit in the wider market. Scientist.com helps research teams drive a project forward. Pharma Observatory places that project in context: who else is working on the same target or indication, who the likely partners and acquirers are, and what the eventual clinical trials are likely to look like. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118907460/en/ Scientist.com's Pharma Observatory brings nearly 1 billion records from ~100 public sources (ClinicalTrials.gov, FDA, USPTO, NIH, SEC) into one cross-referenced model. The public record on biopharma is huge but scattered. ClinicalTrials.gov, the FDA, SEC filings, PubMed, NIH, the USPTO and dozens of other sources each publish part of t
Helical Fusion Awarded Up to JPY 19.2 Billion in Japanese Government Funding to Accelerate Commercial Fusion Power18.11.2026 14:36:00 EET | Press release
Helical Fusion Co., Ltd., a fusion energy company developing commercially viable power plants based on Helical Stellarator technology, has been formally selected for a major Japanese government grant program administered by the Ministry of Economy, Trade and Industry (METI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118128278/en/ The maximum government subsidy is approximately JPY 19.2 billion (USD 126 million). The grant-supported project is scheduled to run through February 2029. Through the Helix Program, Helical Fusion leads overall plant design and systems integration, drawing on research from Japan’s national research institutions and the engineering and manufacturing expertise of approximately 40 companies in Japan. The program aims to turn Japan’s scientific and industrial strengths into practical fusion power. The funding will accelerate three areas of development: Helix HARUKA: Manufacturing and assembly of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
